High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth

Molecular Oncology

Volumn 8, Issue 1, 2014, Pages 93-104

  Leivonen, Suvi Katri ^a,b,c   Sahlberg, Kristine Kleivi ^a,b,d   Mäkelä, Rami ^c   Due, Eldri Undlien ^a,b   Kallioniemi, Olli ^e   Børresen Dale, Anne Lise ^a,b   Perälä, Merja ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^d VESTRE VIKEN HOSPITAL TRUST   (Norway)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Breast cancer; Functional screen; HER2; MicroRNA; Reverse phase protein array

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 134; MICRORNA 193A 5P; MICRORNA 331 3P; MICRORNA 342 5P; MICRORNA 453; MICRORNA 491 5P; MICRORNA 498; MICRORNA 541; MICRORNA 634; MICRORNA 637; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; COHORT ANALYSIS; DOWN REGULATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SURVIVAL TIME;

BREAST CANCER; CLEAVED PARP; CPARP; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; ER; ESTROGEN RECEPTOR; FUNCTIONAL SCREEN; HER2; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAPK; MICRORNA; MIRNA; MITOGEN-ACTIVATED PROTEIN KINASE; REVERSE-PHASE PROTEIN ARRAY; RPPA; UNTRANSLATED REGION; UTR;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84892953786     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.10.001     Document Type: Article

References (47)

1. Adachi R., Horiuchi S., Sakurazawa Y., Hasegawa T., Sato K., Sakamaki T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem. Biophys. Res. Commun. 2011, 411:804-808.
2. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 2011, 9:16-32.
3. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., Mills G.B., van de Vijver M.J., Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
4. Boutros M., Bras L.P., Huber W. Analysis of cell-based RNAi screens. Genome Biol. 2006, 7:R66.
5. Cittelly D.M., Das P.M., Spoelstra N.S., Edgerton S.M., Richer J.K., Thor A.D., Jones F.E. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer 2010, 9:317.
6. Dou S., Yao Y.D., Yang X.Z., Sun T.M., Mao C.Q., Song E.W., Wang J. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. J. Control Release 2012, 161:875-883.
7. Dvinge H., Git A., Graf S., Salmon-Divon M., Curtis C., Sottoriva A., Zhao Y., Hirst M., Armisen J., Miska E.A., Chin S.F., Provenzano E., Turashvili G., Green A., Ellis I., Aparicio S., Caldas C. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013, 497:378-382.
8. Dysvik B., Jonassen I. J-Express: exploring gene expression data using Java. Bioinformatics 2001, 17:369-370.
9. Elmen J., Lindow M., Schutz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjarn M., Hansen H.F., Berger U., Gullans S., Kearney P., Sarnow P., Straarup E.M., Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
10. Enerly E., Steinfeld I., Kleivi K., Leivonen S.-K., Aure M., Russnes H., Rønneberg J., Johnsen H., Navon R., Rødland E., Mäkelä R., Naume B., Perälä M., Kallioniemi O., Kristensen V., Yakhini Z., Børresen-Dale A.-L. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 2011, 6:e16915.
11. Epis M.R., Giles K.M., Barker A., Kendrick T.S., Leedman P.J. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J. Biol. Chem. 2009, 284:24696-24704.
12. Foekens J.A., Sieuwerts A.M., Smid M., Look M.P., de Weerd V., Boersma A.W., Klijn J.G., Wiemer E.A., Martens J.W. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13021-13026.
13. Forman J.J., Legesse-Miller A., Coller H.A. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14879-14884.
14. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
15. Glynn R.W., Miller N., Kerin M.J. 17q12-21-the pursuit of targeted therapy in breast cancer. Cancer Treat Rev. 2010, 36:224-229.
16. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008, 36:D154-D158.
17. Huber W., von Heydebreck A., Sultmann H., Poustka A., Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18(Suppl. 1):S96-S104.
18. Hynes N.E., Dey J.H. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. Cancer Cell 2009, 15:353-355.
19. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
20. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
21. Iorio M.V., Casalini P., Piovan C., Di Leva G., Merlo A., Triulzi T., Menard S., Croce C.M., Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009, 69:2195-2200.
22. Juliano R., Alam M.R., Dixit V., Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 2008, 36:4158-4171.
23. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., Mendell J.R., Mendell J.T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
24. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
25. Kurebayashi J., Otsuki T., Tang C.K., Kurosumi M., Yamamoto S., Tanaka K., Mochizuki M., Nakamura H., Sonoo H. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br. J. Cancer 1999, 79:707-717.
26. Leivonen S.-K., Mäkelä R., Östling P., Kohonen P., Haapa-Paananen S., Kleivi K., Enerly E., Aakula A., Hellström K., Sahlberg N., Kristensen V.N., Borresen-Dale A.L., Saviranta P., Perälä M., Kallioniemi O. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 2009, 28:3926-3936.
27. Lowery A.J., Miller N., Devaney A., McNeill R.E., Davoren P.A., Lemetre C., Benes V., Schmidt S., Blake J., Ball G., Kerin M.J. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009, 11:R27.
28. Lytle J.R., Yario T.A., Steitz J.A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:9667-9672.
29. Magnifico A., Albano L., Campaner S., Campiglio M., Pilotti S., Menard S., Tagliabue E. Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res. 2007, 67:5308-5317.
30. Östling P., Leivonen S.K., Aakula A., Kohonen P., Mäkelä R., Hagman Z., Edsjö A., Kangaspeska S., Edgren H., Nicorici D., Bjartell A., Ceder Y., Perälä M., Kallioniemi O. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 2011, 71:1956-1967.
31. Pan Q., Bao L.W., Kleer C.G., Sabel M.S., Griffith K.A., Teknos T.N., Merajver S.D. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res. 2005, 65:8366-8371.
32. Pasquinelli A.E. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 2012, 13:271-282.
33. Sahlberg K.K., Hongisto V., Edgren H., Makela R., Hellstrom K., Due E.U., Moen Vollan H.K., Sahlberg N., Wolf M., Borresen-Dale A.L., Perala M., Kallioniemi O. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Mol. Oncol. 2013, 7:392-401.
34. Scott G.K., Goga A., Bhaumik D., Berger C.E., Sullivan C.S., Benz C.C. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 2007, 282:1479-1486.
35. Synnestvedt M., Borgen E., Russnes H.G., Kumar N.T., Schlichting E., Giercksky K.E., Karesen R., Nesland J.M., Naume B. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. Acta Oncol. 2013, 52:91-101.
36. Takeshita F., Patrawala L., Osaki M., Takahashi R.U., Yamamoto Y., Kosaka N., Kawamata M., Kelnar K., Bader A.G., Brown D., Ochiya T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2009, 18:181-187.
37. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., Gerald W.L., Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
38. Tay Y., Zhang J., Thomson A.M., Lim B., Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008, 455:1124-1128.
39. Trang P., Medina P.P., Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Homer R., Brown D., Bader A.G., Weidhaas J.B., Slack F.J. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29:1580-1587.
40. Tsang J.S., Ebert M.S., van Oudenaarden A. Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol. Cell 2010, 38:140-153.
41. Uhlmann S., Mannsperger H., Zhang J.D., Horvat E.A., Schmidt C., Kublbeck M., Henjes F., Ward A., Tschulena U., Zweig K., Korf U., Wiemann S., Sahin O. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol. Syst. Biol. 2012, 8:570.
42. Valastyan S., Reinhardt F., Benaich N., Calogrias D., Szasz A.M., Wang Z.C., Brock J.E., Richardson A.L., Weinberg R.A. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032-1046.
43. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2257-2261.
44. Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Patrawala L., Brown D., Bader A.G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70:5923-5930.
45. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab Med. 2007, 131:18-43.
46. Yao Y.D., Sun T.M., Huang S.Y., Dou S., Lin L., Chen J.N., Ruan J.B., Mao C.Q., Yu F.Y., Zeng M.S., Zang J.Y., Liu Q., Su F.X., Zhang P., Lieberman J., Wang J., Song E. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci. Transl. Med. 2012, 4:130-148.
47. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., Huang Y., Hu X., Su F., Lieberman J., Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.